Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access. - Wikidata - awgldk - TriplyDB

Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access.

Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access.

http://www.wikidata.org/entity/Q38418110

about

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, ra Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4).Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens.

P2860

Q31074302-522C88BA-009D-47BD-B64B-1ACB8CAE2A02 Q36294663-5DFD3400-1590-4F87-BDF0-A2BBE75765F1 Q36855625-4B21B049-A93F-484B-9417-85E959AE3A48 Q37034835-E23C8704-F367-4EB2-9C62-FD789EC10257 Q38401143-8DACAB4D-B7CF-4586-B5B8-3FD5958D16C8 Q38406037-42F0BBFD-F305-43D2-AAE8-AE6887D23ADC Q38675771-05EEF35C-3FD3-4B19-82D8-61B88781714F Q40779840-CAA3C8B5-5F1D-4B67-9B09-14E1349E2874 Q55650665-77A3089A-ACA0-407B-8947-0718A11EB4EC

P2860

Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access.

http://www.wikidata.org/entity/Q38418110

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Significant reduction in HIV v ...... g with free healthcare access.

@en

type

label

Significant reduction in HIV v ...... g with free healthcare access.

@en

prefLabel

Significant reduction in HIV v ...... g with free healthcare access.

@en

P1433

Q38418110-C247A7C1-24B0-40A1-91EE-59460B46C73E

P1476

Q38418110-B324FFA2-D614-4911-A074-20C7AAE71EB0

P2093

Q38418110-14B17037-B2A2-42F2-AB95-2922A70C1305

Q38418110-1FABDA75-468A-4F7E-9669-1A5E26D2108D

Q38418110-2E5A1E0D-C267-44F4-97CD-CB32D9D4B1BE

Q38418110-3E5CB5DF-DC1D-4808-A508-B985B7D92DFF

Q38418110-54E776A3-7ACD-4692-9B8C-31EC4388B81E

Q38418110-90A5F9D5-67AB-4E55-BF62-C5FECA030E30

Q38418110-FCE3C999-3F59-41EC-B48A-76A83835C8B1

P2860

Q38418110-011C61B9-7452-4483-A76C-199377ADAB4D

Q38418110-0BADA988-F2F0-4C38-8508-F4082FE4B174

Q38418110-0BD57CCA-127C-4AC7-A348-B075DFE6203F

Q38418110-0FA39C67-CC1A-4424-BAC2-53EA093E0CBC

Q38418110-0FF5D7DF-2AB3-42FF-897D-280534F06BB2

Q38418110-11B6017E-5D4C-4E0E-8BF6-69E1881D0F80

Q38418110-17F7D6FC-F014-411D-AC65-0B81D7A44BA2

Q38418110-1E2EE49B-8E81-4BB6-8326-55B7B9A4BAC5

Q38418110-20F72883-60AA-4A14-BA41-B57F810ADCAF

Q38418110-2F076D07-52E8-4CDA-9CF0-41E2CEA01766

P304

Q38418110-2496CF6F-687D-408E-B8DE-9FEF07AD1829

P31

Q38418110-44C70318-3D4D-436E-95A3-881A64C6E78C

P356

Q38418110-4049EF8D-1E15-4EAF-B258-D5937E7A0047

P407

Q38418110-0F520783-CE18-49FE-93B3-D145ECC83550

P433

Q38418110-297193FD-C20F-42B5-AF15-1247AEE6F283

P478

Q38418110-2ECB1821-DA24-406B-A67B-15AFE92D5B84

P50

Q38418110-367DCDBD-C0B5-48B0-B7E4-496E6DE42F2E

Q38418110-BA8219E0-DE77-4BA6-A93A-0A5B4B3B1BB3

Q38418110-F1E05EDA-0C7E-40A7-898D-510EABD4F09C

P577

Q38418110-6A0DF7E5-EACF-420A-BA09-0AC2216FDF0A

P5875

Q38418110-133D6A36-F05B-4F66-9366-2CE852D6282B

P698

Q38418110-FFE19688-0378-445E-B335-54C46D3E9C3B

P921

Q38418110-51407FCA-4B05-429E-9E7F-CA1919975E76

P356

P1433

Clinical Infectious Diseases

P1476

Significant reduction in HIV v ...... g with free healthcare access.

@en

P2093

Amélie Menard

http://www.w3.org/2001/XMLSchema#string

Constance Delaugerre

http://www.w3.org/2001/XMLSchema#string

FHDH-ANRS CO4

http://www.w3.org/2001/XMLSchema#string

Gilles Pialoux

http://www.w3.org/2001/XMLSchema#string

Jade Ghosn

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Lacombe

http://www.w3.org/2001/XMLSchema#string

Pierre de Truchis

http://www.w3.org/2001/XMLSchema#string

P2860

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Raltegravir with optimized background therapy for resistant HIV-1 infection

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

CD4+ count-guided interruption of antiretroviral treatment

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

P304

463-472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIU834

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Costagliola

P577

2014-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267743978

http://www.w3.org/2001/XMLSchema#string

P698

25344539

http://www.w3.org/2001/XMLSchema#string

P921